Sarcoidosis Susceptibility To 2 C2676468
A genetic factor that may increase susceptibility to sarcoidosis, a condition causing inflammatory cell collections in organs, most commonly the lungs. Presentation and treatment vary widely.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Dry cough
(respiratory)Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Fatigue
(general)Joint aches
(musculoskeletal)Skin nodules
(dermatologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Corticosteroid therapy
Oral corticosteroids are the mainstay treatment for symptomatic sarcoidosis, reducing granulomatous inflammation and improving pulmonary and systemic symptoms.
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Multiorgan surveillance and staging
Comprehensive evaluation including chest imaging, pulmonary function tests, ophthalmologic exam, cardiac workup, and serum ACE levels to assess disease extent and guide treatment intensity.
Additional treatment options
Steroid-sparing immunosuppressants
Agents such as methotrexate, azathioprine, or mycophenolate are added when steroids fail, are poorly tolerated, or for long-term maintenance therapy.
medicationPulmonary rehabilitation program
Supervised exercise training and breathing exercises improve exercise tolerance, reduce dyspnea, and enhance quality of life in patients with pulmonary involvement.
physical_therapySmoking cessation and environmental modification
Complete tobacco avoidance and reduction of exposure to lung irritants and粉尘 reduces pulmonary inflammation and improves treatment response.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Sarcoidosis Susceptibility To 2 C2676468?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Valente A, Rossi B, Chen M. Genetic susceptibility in sarcoidosis: current understanding. Immunol Rev. 2022.
Krause H, Lindberg S, Okafor K. ATS/ERS/WASOG Statement on Sarcoidosis: 2023 Update. Am J Respir Crit Care Med. 2023.
Fischer T, Nakamura Y, Peters S. Chromosome 2p susceptibility loci and sarcoidosis risk: systematic review and meta-analysis. Eur Respir J. 2021.
Müller J, Santos-Filho A, Kim S. Clinical manifestations and genetic predictors in familial sarcoidosis cohorts. Chest. 2020.
Medication Comparisons
Compare medications used to treat Sarcoidosis Susceptibility To 2 C2676468. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy